Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: Relevance for drug efficacy

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 1, 1998, Pages 29-35

  Bédos, Jean Pierre ^a   Azoulay Dupuis, Esther ^a   Moine, Pierre ^c   Muffat Joly, Martine ^a   Veber, Benoit ^a   Pocidalo, Jean Jacques ^a   Vallée, Eric ^b  

^a BICHAT HOSPITAL   (France)

^b Emile Roux Hospital AP HP   (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; LOBAR PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

ANIMALS; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; FEMALE; FLUOROQUINOLONES; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, PNEUMOCOCCAL; QUINOLONES; STREPTOCOCCUS PNEUMONIAE;

EID: 0031848357     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Andes D, Urban A and Craig WA (1995) In-vivo activity of amoxicillin and amoxicillin/clavulanate against penicillin-resistant pneumococci, in Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, A82, p 16, Annual Meeting of the American Society for Microbiology, San Francisco, CA.
2. Aubier M, Lode H, Gialdrani-Grassi G, Huchon G, Hosie J, Regamey C, Segev S, Vester R, Wijnands WJ and Tolstuchow N (1996) Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. J Antimicrob Chemother 37 (Suppl. A):73-82.
3. Azoulay-Dupuis E, Bedos JP, Vallee E, Hardy DJ, Swanson RN and Pocidalo JJ (1991a) Antipneumococcal activity of ciprofloxacin, ofloxacin and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J Infect Dis 163:319-324.
4. Azoulay-Dupuis E, Bedos JP, Vallee E and Pocidalo JJ (1991b) Comparative activity of fluorinated quinolones in acute and subacute S pneumoniae models. J Antimicrob Chemother 28 (Suppl. C):45-53.
5. Azoulay-Dupuis E, Vallee E, Veber B, Bedos JP, Bauchet J and Pocidalo JJ (1992) In-vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multi-resistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob Agents Chemother 36:2698-2703.
6. Baquero F (1995) Pneumococcal resistance to betalactam antbiotics. A global overwiew. Microbiol Drug Res 1:113-120.
7. Bernard L, Nguyen Van J-C and Mainardi J-L (1994) In-vivo selection of Streptococcus pneumoniae resistant to quinolones, including sparfloxacin. Clin Microbiol Infect 1:60-61.
8. Blaser J, Stone BB, Groner MC and Zinner SH (1987) Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31:1054-1060.
9. Canton SM, Pelman J, Jimenez MT, Ramon MS and Gobernado M (1992) In-vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob Agents Chemother 36:558-565.
10. Chin NX and Neu HC (1987) Post antibiotic suppressive effect of ciprofloxacin against gram positive and gram negative bacteria. Am J Med 82 (Suppl. 4A):58-62.
11. Chin NX, Gu JW, Yu KW, Zhang YX and Neu HC (1991) In-vitro activity of sparfloxacin. Antimicrob Agents Chemother 35:567-571.
12. Cooper B, Lawlor M (1989) Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. Am J Med 87:475.
13. Craig WA, Redington J and Ebert SC (1991) Pharmacodynamics of amikacin in-vitro and in experimental infections. J Antimicrob Chemother 27 (Suppl. C):29-40.
14. Davies BL and Maesen FPB (1986) Quinolones in chest infections. J Antimicrob Chemother 18:296-299.
15. Drusano GL, Johnson DE, Rosen M and Standiford HC (1993) Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 37:483-490.
16. Dudley MN (1991) Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med 91 (Suppl 6A):45S-50S.
17. Dudley MN, Mandler HD, Gilbert D, Ericson J, Mayer KH and Zinner SH (1987) Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Am J Med 82:363-368.
18. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC and Schentag JJ (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073-1081.
19. Hyatt JM, Nix DE and Schentag JJ (1994) Pharmacokinetics and pharmacodynamics of ciprofloxacin against similar MIC strains of S pneumoniae, S aureus, and P aeruginosa using kill curve methodology. Antimicrob Agents Chemother 38:2730-2737.
20. Hyatt JM, Mckinnon PS, Zimmer GS and Schentag JJ (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome, Focus on antibacterial agents. Clin Pharmacokinet 28:143-160.
21. Hooper DC and Wolfson JS (1991) Fluoroquinolone antimicrobial agents. N Engl J Med 324:384-394.
22. Lafredo SC, Foleno BD and Fu KP (1993) Induction of resistance of Streptococcus pneumoniae to quinolones in vitro. Chemotherapy 39:36-39.
23. Lee BL, Padula AM, Kimbrough RC, Jones SR, Chaisson RE, Mills J and Sandy MA (1991) Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 325:520.
24. Leggett JE, Ebert S, Fantin B and Craig WA (1991) Comparative dose-effect relations at several dosing intervals for β-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 74 Suppl.:179-84.
25. Moine P, Vercken JB, Chevret S, Chastang C, Gadjos P and The French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit (1994) Severe community-acquired pneumonia. Etiology, epidemiology and prognosis factors. Chest 105:1487-1495.
26. Moine P, Vercken JB, Chevret S, Gajdos P and The French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit (1995) Severe community-acquired pneumococcal pneumonia. Scand J Infect Dis 27:201-206.
27. Montay G, Bruno R, Vergniol JC, Ebmeier M, Le Roux Y, Guimart C, Frydman A, Chassard D and Thebault JJ (1994) Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. J Clin Pharmacol 34:1071-1076.
28. Neuman M (1988) Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet 14:96-121.
29. Nix DE and Schentag JJ (1988) The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. J Clin Pharmacol 28:169-178.
30. Nix DE, Goodwin D, Peloquin CA, Rotella DL and Schentag JJ (1991) Antibiotic tissue penetration and its relevance: Models of tissue penetration and their meaning. Antimicob Agents Chemother 35:1947-1952.
31. Perrez-Tallero E, Garcia-Arenzana JM, Jiminez JA and Peris A (1990) Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. Eur J Clin Microbiol Clin Dis 9:905-906.
32. Peloquin CA, Cumbo TJ, Nix DE, Sands MF and Schentag JJ (1989) Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Arch Intern Med 149:2269-2273.
33. Piddock LJV (1994) New quinolones and gram-positive bacteria. Antimicrob Agents Chemother 38:163-169.
34. Schentag JJ, Nix DE and Forrest A (1993) Pharmacodynamics of the fluoroquinolones, in Quinolone Antimicrobial Agents (Hooper DC, Wolfson JS, ed) 2nd ed, pp 259-271, American Society for Microbiology, Washington, DC.
35. Scully BE (1993) Therapy of respiratory tract infections with quinolone antimicrobial agent, in Quinolone Antimicrobial Agents (Wolfson JS and Hooper DC, eds) 2nd ed, pp. 339-362, American Society for Microbiology, Washington, DC.
36. Stein GE (1996) Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 23 (Suppl 1):S19-S24.
37. Sullivan MC, Cooper BW, Nightingale CH, Quintiliani R and Lawlor MT (1993) Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. Antimicrob Agents Chemother 37:234-239.
38. Thys JP, Jacobs F and Byl B (1991) Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 10:304-315.
39. Vallee E, Azoulay-Dupuis E, Pocidalo JJ and Bergogne-Berezin E (1991) Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. J Antimicrob Chemother 28 (Suppl. C):39-44.
40. Vallee E, Azoulay-Dupuis E, Bauchet J, and Pocidalo JJ (1992) Kinetic disposition of temafloxacin and ciprofloxacine in a murine model of pneumococcal pneumonia. relevance for drug efficacy. J Pharmacol Exp Ther 262:1203-1208.
41. Vesga O and Craig WA (1995) Activity of levofloxacin against penicillin-resistant Streptococcus pneumoniae in normal and neutropenic mice, in Program and Abstracts of the 36h Interscience Conference on Antimicrobial Agents and Chemotherapy, A59, p 12, Annual Meeting of the American Society for Microbiology, New Orleans, LA.
42. Vesga O, Conklin R, Stamstad T and Craig WA (1995) In-vivo pharmacodynamic activity of sparfloxacin against multiple bacterial pathogens, in Program and Abstracts of the 36h Interscience Conference on Antimicrobial Agents and Chemotherapy, A65, p 13, Annual Meeting of the American Society for Microbiology, New Orleans, LA.
43. Vogelman B, Gudmunsson S, Leggett J, Turnidge J, Ebert S and Craig WA (1988) Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158:831-847.